SPRY
ARS Pharmaceuticals, Inc.Company with tickers: SPRY
CIK
1671858
CUSIP
82835W108
Shares Outstanding
99,303,262
13F Activity (30d)
134 filings
129 filers
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-05-14 | 75,516 | $8.01 | $604,883 |
| 2026-05-11 | 50,012 | $8.74 | $437,105 |
| 2026-05-08 | 51,727 | $9.00 | $465,543 |
| 2026-05-07 | 83,989 | $9.28 | $779,418 |
| 2026-05-06 | 11,355 | $9.03 | $102,536 |
| 2026-05-05 | 15,111 | $8.83 | $133,430 |
| 2026-05-04 | 61,822 | $8.56 | $529,196 |
| 2026-05-01 | 15,668 | $8.26 | $129,418 |
| 2026-04-30 | 78 | $7.84 | $612 |
| 2026-04-29 | 275,080 | $7.94 | $2,184,135 |
| 2026-04-28 | 420,744 | $7.95 | $3,344,915 |
| 2026-04-27 | 156,280 | $8.29 | $1,295,561 |
| 2026-04-24 | 46 | $8.30 | $382 |
| 2026-04-21 | 20,014 | $8.18 | $163,715 |
| 2026-04-20 | 16,064 | $8.18 | $131,404 |
| 2026-04-16 | 222,388 | $8.02 | $1,783,552 |
| 2026-04-15 | 79 | $8.14 | $643 |
| 2026-04-13 | 20,345 | $8.05 | $163,777 |
| 2026-04-09 | 441,723 | $8.19 | $3,617,711 |
| 2026-04-07 | 31,766 | $8.39 | $266,517 |
| 2026-04-06 | 22,370 | $8.30 | $185,671 |
| 2026-04-02 | 16,436 | $8.11 | $133,296 |
| 2026-04-01 | 220 | $8.03 | $1,767 |
| 2026-03-31 | 68,546 | $7.82 | $536,030 |
| 2026-03-30 | 111,936 | $8.07 | $903,324 |
| 2026-03-27 | 58,080 | $8.56 | $497,165 |
| 2026-03-26 | 41,318 | $7.90 | $326,412 |
| 2026-03-25 | 2,918 | $7.54 | $22,002 |
| 2026-03-24 | 7,936 | $7.67 | $60,869 |
| 2026-03-23 | 213,348 | $8.17 | $1,743,053 |
| 2026-03-19 | 189 | $8.30 | $1,569 |
| 2026-03-18 | 26,166 | $8.89 | $232,616 |
| 2026-03-17 | 3,454 | $8.70 | $30,050 |
| 2026-03-16 | 54,637 | $8.39 | $458,404 |
| 2026-03-13 | 1,944 | $8.24 | $16,019 |
| 2026-03-12 | 62,076 | $8.38 | $520,197 |
| 2026-03-10 | 3,324 | $9.05 | $30,082 |
Showing 1–37 of 37 settlements